Overview
ABT market data
Price History
ABT price chart
Valuation & Profitability
- P/E (TTM)
- 35.52 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $3.73 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.58 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 2.3% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 11.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $81.97 – $137.49 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $192.7B · P/B 4.18 · P/S 4.14.
Company News
Congressman Ditches Blue Chip Stocks for Municipal Bonds: Here Are the SalesBenzinga · Aug 13, 2026, 9:45 PM
Wolfe Research Upgrades Abbott Laboratories to Outperform, Announces $130 Price TargetBenzinga · Aug 13, 2026, 5:13 PM
The U.S. Labor Market Is Weakening. These 2 Dividend Stocks Look Built to Weather a RecessionThe Motley Fool · Aug 11, 2026, 10:15 PM
Abbott Partners With Google Health To Combine Glucose Insights From Abbott's Lingo Biowearable With Google's Expertise In AI To Make Personalized Metabolic Insights More ActionableBenzinga · Aug 11, 2026, 1:09 PM
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · Jul 31, 2026, 8:15 PM
UBS Maintains Buy on Abbott Laboratories, Lowers Price Target to $125Benzinga · Jul 28, 2026, 7:15 PM
Implicity’s Next-Generation ILR ECG Analyzer Earns FDA ClearanceGlobenewswire Inc · Jul 28, 2026, 12:15 PM
Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Option For Colorectal Cancer, With Freenome Earning $100M Milestone PaymentBenzinga · Jul 27, 2026, 12:06 PM
Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS InsiderGlobenewswire Inc · Jul 24, 2026, 2:15 PM
Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $112Benzinga · Jul 17, 2026, 6:22 PM